Press Room

bioTheranostics, Formerly Arcturus Bioscience, Inc., Announces Presentation at the 2006 Annual BIO Conference

Divesture of Life Science Products Allows Clear Focus on Molecular Cancer Profiling Opportunity

CARLSBAD, Calif., April 12 /PRNewswire/ -- bioTheranostics, formerly known as Arcturus Bioscience, Inc., announced today that Antonius Schuh, Ph.D., the Company's Chief Executive Officer, will present at the Annual BIO Conference on Wednesday, April 12, at 11:15 a.m. CST in the Room D of the McCormick Place South in Chicago.

Dr. Schuh will provide an update on the company's divesture of its products and assets related to the life science research market and bioTheranosticss focus on its molecular cancer profiling technologies and business opportunities for tumor identification, patient prognosis and prediction of response to cancer therapies. He will address the company's development and commercial plans in the context of its commercial cancer diagnostic partnerships with Quest, LabCorp and Agendia.

About bioTheranostics

bioTheranostics, formerly Arcturus Bioscience, Inc., is a leader in describing disease at the molecular level to enable molecular medicine and the development of proprietary technologies for diagnostic applications in oncology. These technologies include the Molecular Cancer Identification (MCID) technology which is based upon a set of clinically validated molecular signatures relating to 90% of the most common cancers, and the Breast Cancer Recurrence (BCR) technology, which is based upon a proprietary biomarker index for the prognosis of breast cancer recurrence risk and metastatic potential. Commercialization of the MCID Technology commenced with its licensing partners Quest Diagnostics, and Laboratory Corporation of America and Agendia BV for their Cancer of Unknown Primary (CUP) diagnostic service. Quest Diagnostics has also licensed the BCR technology for the development of a diagnostic service. bioTheranostics technologies and intellectual properties position the company to address the multi-billion dollar market opportunities associated with the development and commercialization for additional cancer diagnostics and inventions to cost-effectively improve patient prognosis and response prediction in cancer therapy. bioTheranostics has relocated its headquarters from Mountain View, California to Carlsbad, California. Please visit the bioTheranostics website at http://www.biotheranostics.com for more information.

| TOP |